Antiviral Drug
- All
- News
- Videos
-
Covid Pill Shows Rapid Clearance Of Virus, Says Japan Pharma Firm
An experimental treatment from Shionogi & Co Ltd has shown rapid clearance of the virus that causes COVID-19, according to new data, the Japanese drug maker said on Sunday.
-
Positive Results In Phase 3 Trial Of Covid Pill, Says Hetero Pharma Group
Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.
-
Pfizer Covid Pill Europe's First Approved Oral Treatment Against Covid
The EU's drug watchdog approved Pfizer's coronavirus pill on Thursday, making it the first oral antiviral treatment for the disease to be authorised in Europe.
-
South Korea Authorises Emergency Use Of Pfizer's Antiviral Covid Pill
South Korea authorised for emergency use Pfizer's antiviral pills targeting COVID19 as the first of its kind to be introduced in South Korea, the Ministry of Food and Drug Safety.
-
Pfizer Covid Pill Nearly 90% Effective, Works On Omicron, Shows Lab Data
Pfizer Inc on Tuesday said final analysis of its antiviral COVID-19 pill still showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast
-
Game-Changing Made-In-India Anti-Covid Pills Could Be Cleared For Use In Days
Emergency Use Authorisation for the Merck drug Molnupiravir -- an oral antiviral medicine for the treatment of mild-to-moderate COVID-19 -- is likely "within days", Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR, told NDTV today.
-
Pfizer Says Its Antiviral Pill Cuts Risk Of Severe Covid By 89%
A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease.
-
WHO Aims To Help Poorer Countries Access Vaccine With $10 Covid Pills
A World Health Organization-led programme to ensure poorer countries get fair access to COVID-19 vaccines, tests and treatments aim to secure antiviral drugs for patients with mild symptoms for as little as $10 per course.
-
Merck COVID-19 Pill Has Vital Indian Link, Maker Sees Stock Price Jump
India's Everest Organics Ltd said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.
-
2 Indian Firms Seek To End Current Trials Of Merck's Anti-Covid Pill
Two drugmakers in the country have requested permission to end their late-stage trials on Merck & Co's experimental antiviral drug molnupiravir in moderate COVID-19 patients.
-
India's Remdesivir Production Reached 1.2 Crore Vials A Month In June: Centre
India's production capacity of Remdesivir increased from 38.8 lakh vials per month in mid-April to 122.49 lakh vials per month in June 2021, and as on date, there is no shortage of the antiviral drug in any state or union territory, the Centre said.
-
Early Antiviral Response In Nose May Determine Severity Of Covid: Study
The course of severe COVID-19 may be determined by the body's antiviral response to initial infection, according to a study which opens up new avenues for early drug interventions that could prevent severe disease.
-
US Delivers 1,25,000 Remdesivir Vials To India, 4th Covid Relief Shipment
India received 1,25,000 vials of antiviral drug Remdesivir, the fourth Covid relief shipment, from the United States on Sunday as New Delhi fights a deadly second wave that has strained its healthcare system.
-
Remdesivir Only On Medical Prescription To Severe Covid Patients: Centre
Antiviral drug Remdesivir is to be administered only after a medical prescription and limited to severe condition of COVID-19 patients strictly as per medical protocol, the Centre told the Supreme Court on Friday.
-
Pfizer Chief Says Oral Drug For COVID-19 Could Be Ready Next Year: Report
Pfizer CEO Albert Bourla has said that an oral drug for treating coronavirus could be ready next year, adding that the company is working on two antivirals, an oral and an injectable.
-
Covid Pill Shows Rapid Clearance Of Virus, Says Japan Pharma Firm
An experimental treatment from Shionogi & Co Ltd has shown rapid clearance of the virus that causes COVID-19, according to new data, the Japanese drug maker said on Sunday.
-
Positive Results In Phase 3 Trial Of Covid Pill, Says Hetero Pharma Group
Drug firm Hetero on Saturday announced positive results of Phase III trials of Movfor (Molnupiravir), an investigational oral antiviral COVID-19 medicine.
-
Pfizer Covid Pill Europe's First Approved Oral Treatment Against Covid
The EU's drug watchdog approved Pfizer's coronavirus pill on Thursday, making it the first oral antiviral treatment for the disease to be authorised in Europe.
-
South Korea Authorises Emergency Use Of Pfizer's Antiviral Covid Pill
South Korea authorised for emergency use Pfizer's antiviral pills targeting COVID19 as the first of its kind to be introduced in South Korea, the Ministry of Food and Drug Safety.
-
Pfizer Covid Pill Nearly 90% Effective, Works On Omicron, Shows Lab Data
Pfizer Inc on Tuesday said final analysis of its antiviral COVID-19 pill still showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients, and recent lab data suggests the drug retains its effectiveness against the fast
-
Game-Changing Made-In-India Anti-Covid Pills Could Be Cleared For Use In Days
Emergency Use Authorisation for the Merck drug Molnupiravir -- an oral antiviral medicine for the treatment of mild-to-moderate COVID-19 -- is likely "within days", Dr Ram Vishwakarma, Chairman of the Covid Strategy Group, CSIR, told NDTV today.
-
Pfizer Says Its Antiviral Pill Cuts Risk Of Severe Covid By 89%
A trial of Pfizer Inc's experimental antiviral pill for COVID-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease.
-
WHO Aims To Help Poorer Countries Access Vaccine With $10 Covid Pills
A World Health Organization-led programme to ensure poorer countries get fair access to COVID-19 vaccines, tests and treatments aim to secure antiviral drugs for patients with mild symptoms for as little as $10 per course.
-
Merck COVID-19 Pill Has Vital Indian Link, Maker Sees Stock Price Jump
India's Everest Organics Ltd said on Tuesday it had started making the active pharmaceutical ingredient (API) for a generic version of Merck & Co's experimental antiviral drug molnupiravir to treat mild to moderate COVID-19.
-
2 Indian Firms Seek To End Current Trials Of Merck's Anti-Covid Pill
Two drugmakers in the country have requested permission to end their late-stage trials on Merck & Co's experimental antiviral drug molnupiravir in moderate COVID-19 patients.
-
India's Remdesivir Production Reached 1.2 Crore Vials A Month In June: Centre
India's production capacity of Remdesivir increased from 38.8 lakh vials per month in mid-April to 122.49 lakh vials per month in June 2021, and as on date, there is no shortage of the antiviral drug in any state or union territory, the Centre said.
-
Early Antiviral Response In Nose May Determine Severity Of Covid: Study
The course of severe COVID-19 may be determined by the body's antiviral response to initial infection, according to a study which opens up new avenues for early drug interventions that could prevent severe disease.
-
US Delivers 1,25,000 Remdesivir Vials To India, 4th Covid Relief Shipment
India received 1,25,000 vials of antiviral drug Remdesivir, the fourth Covid relief shipment, from the United States on Sunday as New Delhi fights a deadly second wave that has strained its healthcare system.
-
Remdesivir Only On Medical Prescription To Severe Covid Patients: Centre
Antiviral drug Remdesivir is to be administered only after a medical prescription and limited to severe condition of COVID-19 patients strictly as per medical protocol, the Centre told the Supreme Court on Friday.
-
Pfizer Chief Says Oral Drug For COVID-19 Could Be Ready Next Year: Report
Pfizer CEO Albert Bourla has said that an oral drug for treating coronavirus could be ready next year, adding that the company is working on two antivirals, an oral and an injectable.
